Introduction {#sec1-1}
============

Atrial fibrillation (AF) is the most common sustained arrhythmia, and ablation procedures for AF have been shown to be safe and effective in a large number of cases worldwide ([@ref1]--[@ref4]). However, the recurrence rates of AF after catheter ablation are still considerably high ([@ref5], [@ref6]). Pulmonary vein (PV) reconnection due to ineffective ablation lesions has been identified as the main cause of AF recurrence ([@ref7], [@ref8]), and catheter--tissue contact is essential for effective ablation lesions ([@ref4], [@ref9], [@ref10]). However, an accurate measurement of lesions and understanding the limitations of the contact force (CF) are crucial for avoiding complications ([@ref11]). In recent years, radiofrequency (RF) catheter ablation with CF sensing, a novel method, has been claimed to be potentially responsible for effective ablation. When using it, the catheter--tissue CF can be measured at the catheter tip with fiber optic or magnetic sensors ([@ref12]).

The safety and effectiveness of CF-sensing catheters have been evaluated in ex vivo models ([@ref10], [@ref13]) and in vivo experimental studies ([@ref14], [@ref15]) before their recent application in humans. Experimental data in previous studies have demonstrated a strong relationship between CF and lesion size when using an RF current for catheter ablation ([@ref14]). However, the efficacy and safety of CF-sensing catheters, particularly for reducing the rate of complications, remain controversial.

The purpose of this meta-analysis was to evaluate the efficacy and safety of catheter AF ablation using CF-sensing catheters.

Methods {#sec1-2}
=======

Literature search {#sec2-1}
-----------------

Electronic databases, such as PubMed, EMBASE, Wanfang Data, China National Knowledge Infrastructure (January 1, 1998--2016), and Cochrane Controlled Trials Register, for reports on all randomized controlled trials (RCTs) or non-randomized observational studies (NROSs) published in English or Chinese were searched using the following medical subject headings, "contact force-sensing catheter," "ablation," and "atrial fibrillation," to capture data on catheter AF ablation using CF-sensing catheters. The abstracts of all identified RCTs or NROSs were independently screened by two reviewers.

Study selection and quality assessment {#sec2-2}
--------------------------------------

Studies fulfilling the following criteria were included: ([@ref1]) patients undergoing AF ablation using CF-sensing catheters and standard non-CF (NCF)-sensing catheters, ([@ref2]) patients with paroxysmal AF (PAF) or persistent AF (Per AF), and ([@ref3]) human studies conducted in adults who were 18 years and older. Non-comparative trials, case reports, editorials, and reviews were excluded from this study.

We used PRISMA guidelines in this meta-analysis. Individual studies were checked for the following characteristics: adequate sequence generation, allocation concealment, attrition less than 15%, blinded assessment, intent-to-treat analysis, complete follow-up, and adequate AF monitoring.

Data abstraction {#sec2-3}
----------------

The citations were also reviewed, and data were independently abstracted by two reviewers; disagreements were resolved by discussions. Abstracted data included the following: ([@ref1]) study type, study size, study design, CF catheter used, mean CF used, and follow-up; ([@ref2]) age and gender; ([@ref3]) AF recurrence within 12 months (primary outcomes); ([@ref4]) occurrence of acute PV reconnection; ([@ref5]) primary safety endpoint including device-related serious adverse events (events were classified as major and minor complications; major complications included in-hospital death, cardiac perforation, cardiac effusion or tamponade, stroke, PV stenosis, esophageal fistula, severe hemoptysis, phrenic nerve lesion, and thromboembolic event, whereas minor complications were mainly related to vascular access complications, including femoral/subclavian hematoma and arteriovenous fistula); and ([@ref6]) procedure duration, ablation time, fluoroscopy duration, and radiation dose.

Statistical analysis {#sec2-4}
--------------------

Statistical analysis was performed using Cochrane RevMan version 5 (The Cochrane Collaboration, UK), and results were expressed as weighted mean differences (MDs) and relative risk for continuous and dichotomous outcomes, respectively, with 95% confidence intervals (CIs). Outcomes were pooled using the random-effects model when the heterogeneity was moderate or high (I^2^\>50%). However, the fixed-effects model was used when the heterogeneity was low (I^2^\<50%). Radiation doses used among the included studies were compared using a standard MD (SMD) as different radiation units had been used. The present study assessed the heterogeneity between studies using the Cochran's Q statistic and I^2^ index. All statistical testing was two tailed with statistical significance at p\<0.05.

Results {#sec1-3}
=======

The electronic search identified 193 references from PubMed, 167 from EMBASE, and 15 from the Cochrane Central Register of Controlled Trials. Among these abstracts, 329 were excluded. The full manuscripts for the remaining 46 studies were retrieved for a detailed review, and 27 were further excluded. Finally, 19 studies ([@ref16]--[@ref34]) \[4 RCTs ([@ref16]--[@ref19]), 2 retrospective cohort studies ([@ref20], [@ref21]), and 13 NROSs ([@ref22]--[@ref34])\] were identified that compared the safety and efficacy of CF-sensing or NCF-sensing catheters in the setting of AF ablation. Information relevant to the literature search is shown in [Figure 1](#F1){ref-type="fig"}.

![Flow diagram of the literature search stages](AJC-17-82-g001){#F1}

Publication bias {#sec2-5}
----------------

No significant publication bias was found for the primary outcome (AF recurrence at the follow-up) as assessed by a funnel plot ([Fig. 2](#F2){ref-type="fig"}).

![Funnel plot for the assessment of publication bias for the primary outcome. Effect size is plotted on the x -axis and SE on the y-axis.\
AF - atrial fibrillation; RR - risk ratio; SE - standard error](AJC-17-82-g002){#F2}

Baseline patient characteristics {#sec2-6}
--------------------------------

Baseline patient characteristics are provided in [Table 1](#T1){ref-type="table"}. A total of 4053 patients were included in the CF-sensing (n=1546) and NCF-sensing (n=2507) catheter groups.

###### 

Baseline clinical characteristics and follow-up of the patients

                           Type of study                                            AF (CF/NCF)        PAF (CF/NCF)      PerAF (CF/NCF)   Mean age y(CF/NCF)     Male, n(%) (CF/NCF)      Hypertension n(%) (CF/NCF)   Diabetes, n(%) (CF/NCF)   LA size mm (CF/NCF)   EF (%) (CF/NCF)       CF Catheter                           Mean CF, g   Follow up months
  ------------------------ -------------------------------------------------------- ------------------ ----------------- ---------------- ---------------------- ------------------------ ---------------------------- ------------------------- --------------------- --------------------- ------------------------------------- ------------ ------------------
  Reddy 2015 (TOCCASTAR)   prospective, randomized, controlled, multicenter study   295 (152/143)      295 (152/143)     0                59.6±9.3 /61.0±10.8    100 (65.8) /91 (63.6)    75 (49.3) /69 (48.3)         16 (10.5) /17 (11.9)      39.9±5.9 /39.3±4.5    62.4±7.1 /62.4±6.2    TactiCath                             NR           12
  Nakamura 2015            prospective, randomized, controlled study                120 (60/60)        80 (38/42)        40 (22/18)       64/64.5                44 (73.3) /45 (75.0)     27 (45.0) /36 (60.0)         8 (13.3) /10 (16.7)       40±6/39±5             67/65                 Thermocool SmartTouch                 18           12
  Wolf 2015                Prospective non-randomized study                         36 (24/12)         27 (18/9)         9 (6/3)          58.6±11.3 /62.2±8.5    19 (79.2) /11 (91.7)     8 (33.3) /6 (50.0)           2 (8.3) /0 (0)            42.0±3.6 /43.0±4.3    56.0±7.9 /58.1±8.0    Thermocool SmartTouch                 17.8         NR
  Itoh 2015                Prospective non-randomized study                         100 (50/50)        100 (50/50)       0                65±11 /61±10           30 (60) /31 (62)         32 (64) /26 (52)             5 (10) /8 (16)            37±7 /38±6            65±10 /65±7           Thermocool SmartTouch                 NR           12
  Makimoto 2015            Prospective non-randomized study                         70 (35/35)         44 (19/25)        26 (16/10)       67±9 /60±11            24 (69) /27 (77)         25 (71) /29 (83)             4 (11) /4 (11)            44±6 /45±6            60±7 /60±6            Thermocool SmartTouch                 16           12
  Sigmund 2015             Prospective case- matched control trial                  198 (99/99)        126 (62/64)       72 (37/35)       59.5±9.6 /59.5±9.4     71 (72) /68 (69)         46 (47) /52 (53)             4 (4) /3 (3)              40±6 /41±6            56±5 /57±7            Thermocool SmartTouch                 NR           12
  G. Lee 2015              retrospective observational cohort study                 1515 (510/1005)    656 (238/418)     750 (255/495)    60.5±11.0 /60.8±11.3   349 (68.4) /264 (63.6)   77 (15) /140 (14)            31 (6) /50 (5)            NR                    NR                    Thermocool SmartTouch                 NR           NR
  Kimura 2014              prospective, randomized, controlled, study               38 (19/19)         28 (15/13)        10 (4/6)         62.5±10.1 /57.3±8.6    12 (63) /17 (89)         13 (68.4) /9 (47.4)          3 (15.8) /4 (21.1)        41.3±7.8 /42.0±6.8    65.7±5.2 /62.4±11.8   Thermocool SmartTouch                 NR           6
  Casella 2014             prospective, randomized, controlled, study               55 (20/35)         55 (20/35)        0                58±10 /56±13           16 (80) /28 (80)         6 (30) /12 (34)              NR                        43.2±6.4 /41.9±5.5    62.3±7.4 /62.0±7.8    Tacticath                             16           12
  Ullah 2014               Prospective non-randomized multicenter study             100 (50/50)        NR                NR               63/62                  41 (82) /39 (78)         11 (22) /7 (14)              3 (5) /2 (4)              4.4±0.6 /4.4±0.6      NR                    Thermocool SmartTouch                 13           12
  Sciarra 2014             Prospective non-randomized study                         42 (21/21)         42 (21/21)        0                59.7±9.1 /54.6±11.0    18 (86) /18 (86)         NR                           1 (5) /2 (10)             35±7 /36±6            56±5 /55±5            Thermocool SmartTouch                 NR           2.5
  Wakili 2014              Prospective non-randomized study                         67 (32/35)         39 (18/21)        28 (14/14)       63.6±1.7 /59.3±1.9     21 (65.6) /23 (65.7)     21 (65.6) /25 (71.4)         NR                        43.2±0.9 /42.1±0.9    68.5±2.2 /65.0±1.9    Tacticath                             17.4         12
  Andrade 2014             Prospective non-randomized study                         75 (25/50)         75 (25/50)        0                58.8±12.7 /58.6±11.0   19 (76) /43 (86)         NR                           NR                        32.4±14.2 /39.2±4.7   63.3±5.5 /59.9±5.4    Thermocool SmartTouch                 NR           13.2±0.9
  Wutzler 2014             Prospective non-randomized study                         143 (31/112)       104 (19/85)       39 (12/27)       59.8±10.9 /60.9±10.2   21 (67.7) /71 (63.4)     20 (64.5) /58 (51.8)         3 (9.7) /10 (8.9)         41.5±6.1 /42.4±6.7    56.8±4.9 /55.6±3.1    TactiCath                             26.8         12
  Marijon 2014             Prospective non-randomized study                         60 (30/30)         60 (30/30)        0                59.9±9 /61.0±10        21 (70.0) /22 (73.3)     NR                           NR                        NR                    64.7±4 /65.4±5        Thermocool SmartTouch                 21.7         12
  Akca 2014                Prospective non-randomized study                         449 (143/306)      NR                NR               55.7±15.1 /51.7±16.6   NR                       NR                           NR                        NR                    NR                    Thermocool SmartTouch and Tacticath   NR           NR
  Jarman 2014              Retrospective case--control study                        600 (200/400)      276 (92/184)      324 (108/216)    63±12 /61±10           149(74.5) /282(70.5)     80 (40) /119 (30)            21 (11) /34 (9)           42±7 /44±7            NR                    Thermocool SmartTouch                 NR           11.4±4.7
  Haldar 2012              Prospective non-randomized study                         40 (20/20)         14 (7/7)          26 (13/13)       63±14 /61±12           15 (75) /11 (55)         7 (35) /6 (30)               NR                        42±8 /41±5            57±12 /59±10          Thermocool SmartTouch                 NR           NR
  Martinek 2012            Prospective non-randomized study                         50 (25/25)         50 (25/25)        0                60.5±9.5 /57.4±11.6    12 (48) /17 (68)         10 (40) /12 (48)             3 (12) /1 (4)             39±6 /37±6            53±4 /53±3            Thermocool SmartTouch                 NR           NR
  Mean                                                                                                                                                                                                                                                                                                                             18.3         
  Total                                                                             4053 (1546/2507)   2071 (849/1222)   1324 (487/837)                                                                                                                                                                                                         

AF - atrial fibrillation; CF - contact force; NR - not reported; PAF - paroxysmal atrial fibrillation; Per AF - persistent atrial fibrillation. Statistical analysis was performed using the Cochrane RevMan version 5 software

Ten studies provided detailed information on the PAF and/or Per AF patient subgroups, and relevant information was abstracted to compare the efficacy and safety in the AF, PAF, and/or Per AF subgroups.

Efficacy of AF ablation using CF-sensing catheters {#sec2-7}
--------------------------------------------------

AF recurrence within 12 months was compared in the AF (13 studies), PAF (9 studies), and Per AF (3 studies) subgroups. In the AF and PAF subgroups, AF recurrence significantly improved using CF-sensing catheters compared with that using NCF-sensing catheters in the AF \[31.1% vs. 40.5%; risk ratio (RR)=0.82; 95% CI, 0.73--0.93; I^2^=32%; p=0.001\] and PAF (25.3% vs. 40.0%; RR=0.76; 95% CI, 0.63--0.91; I^2^=21%; p=0.004) subgroups, which was similar with a previous meta-analysis that included nine studies ([@ref35]). In the Per AF subgroup, the rate of AF recurrence was numerically lower in the CF group than in the NCF group; however, this did not reach statistical significance (49.7% vs. 55.8%; RR=0.93; 95% CI, 0.77--1.12; I^2^=53%; p=0.43; [Fig. 3a](#F3){ref-type="fig"}).

![(a) Forest plot showing the RR and 95% CI for AF recurrence within 12 months for studies comparing the CF and NCF groups. (b) Forest plot showing the RR and 95% CI for the occurrence of acute PV reconnection for studies comparing the CF and NCF groups](AJC-17-82-g003){#F3}

Moreover, seven studies provided data on the rate of acute PV reconnection, and no evidence of heterogeneity was found among the studies (I^2^=0%). The acute PV reconnection significantly improved using CF-sensing catheters compared with that using NCF-sensing catheters (10.1% vs. 24.2%; RR=0.45; 95% CI, 0.32--0.63; I^2^=0%; p=0.00001; [Fig. 3b](#F3){ref-type="fig"}).

The CF used in the included studies ranged between 10 and 40 g, and the mean CF used was 18.3 g.

Safety of AF ablation using CF-sensing catheters {#sec2-8}
------------------------------------------------

As shown in [Figure 4](#F4){ref-type="fig"}, 11 studies assessed the incidence rate of major complications, and no evidence of heterogeneity was found among these studies (I^2^=0%). The incidence rate of major complications was significantly lower in the CF group than in the NCF group (1.8% vs. 3.1%; OR=0.59; 95% CI, 0.37--0.95; I^2^=0%; p=0.03). The incidence rate of minor complications was numerically lower in the CF group than in the NCF group; however, the results did not reach statistical significance (5.4% vs. 5.8%; OR=1.22; 95% CI, 0.78--1.92; I^2^=0%; p=0.37).

![Forest plot showing odds ratio and 95% CI for the incidence rate of major complications and minor complications for studies comparing the CF and NCF groups](AJC-17-82-g004){#F4}

Most included studies provided data on procedure parameters such as procedure duration, ablation time, fluoroscopy duration, and radiation dose in the AF and PAF subgroups. [Figure 5](#F5){ref-type="fig"} show that in the AF subgroup, the procedure duration \[MD=-28.35; 95% CI, -39.54 to -17.16; I^2^=85%; p=0.00001\], ablation time(MD=-3.8; 95% CI, -6.6 to -1.0; I^2^=76%; p=0.008), fluoroscopy duration (MD=-8.18; 95% CI, -14.11 to -2.24; I^2^=97%; p=0.007), and radiation dose (SMD=-0.75; 95% CI, -1.32 to -0.18; I^2^=90%; p=0.01) significantly reduced in the CF-guided group compared with in the NCF group. In the PAF subgroup, the procedure duration (MD=-49.64; 95% CI, -76.5 to -22.78; I^2^=83%; p=0.0003), ablation time (MD=-8.68; 95% CI, -13.83 to -3.52; I^2^=67%; p=0.001), fluoroscopy duration (MD=-13.9; 95% CI, -22.25 to -5.55; I^2^=93%; p=0.0001), and radiation dose (SMD=-0.56; 95% CI, -1.04 to -0.08; I^2^=73%; p=0.02) significantly reduced in the CF-guided group compared with in the NCF group.

![(a--c) Forest plot showing the unadjusted difference in the mean procedure duration, ablation time, and fluoroscopy duration for studies comparing the CF and NCF groups. (d) Forest plot showing the standard difference in the mean radiation dose for studies comparing the CF and NCF groups](AJC-17-82-g005){#F5}

Discussion {#sec1-4}
==========

This meta-analysis showed that in contrast to AF and PAF ablation performed using NCF-sensing catheters, the use of CF-sensing catheters resulted in a significantly lower rate of acute PV reconnection and AF recurrence during the 12-month follow-up as well as reduced major complications and procedure parameters related to safety.

Achieving a lasting conduction block during the ablation procedure depends on a multitude of factors, including tissue depth, electrode--tissue interface temperature, and electrode tip--tissue contact pressure ([@ref29]). Insufficient CF during initial lesion formation may result in edema and ineffective non-transmural lesions that allow subacute PV reconnection when the edema resolves ([@ref2], [@ref12]), whereas excessive contact can cause collateral tissue injury ([@ref31], [@ref32], [@ref36]). Conventionally, the adequacy of contact between a catheter tip and tissue has been assessed using a combination of subjective factors and objective ablation parameters. Unfortunately, these parameters are poor predictors as they are unreliable and difficult to use ([@ref29], [@ref37]).

CF-sensing catheters offer a new paradigm in the invasive management of AF. Using these, continuous catheter--tissue CF can be measured, which ensures not only the optimal initial placement of the catheter but also the ability to detect catheter dislodging/sliding in real time ([@ref31]). According to these features, the use of CF technology resulted in a significant reduction in the rate of acute PV reconnection and AF recurrence after AF ablation compared with the use of NCF.

However, it is a challenge to identify the optimal CF that should be applied during AF ablation to ensure adequate lesion formation, avoiding collateral tissue injury by the mean time.

The TOCCATA study ([@ref38]) demonstrated that when PV isolation was performed with an average CF of \<10 g, AF recurrence was 100%. When the average CF was \>20 g, AF recurrence reduced to 20%. A recent published study ([@ref39]) demonstrated that a CF threshold of \>12 g predicts a complete lesion with high specificity. In the TOCCASTAR study, Reddy et al. ([@ref16]) demonstrated that ablation with an optimal CF (≥90% of lesions created with a CF of ≥10 g) resulted in a significantly higher success rate than that obtained for PV isolation with a non-optimal CF. The EFFICAS II study ([@ref40]) prospectively applied CF guidelines for ensuring durable isolation of the PV of PAF patients, which demonstrated a target CF of 20 g; a range of 10--30 g resulted in a superior rate of durable PV isolation than the similar protocol without guidelines. The SMART-AF trial, a prospective, multicenter, non-randomized study ([@ref41]), demonstrated that with an average CF of 17.9±9.4 g, 72.5% of patients were free from AF recurrence in a 12-month follow-up. The current meta-analysis provided important information regarding the use of an optimal average CF of 18.3 g (range, 10--40 g), with acceptable recurrence and complication rates.

Whether the use of CF-sensing catheters can decrease the rate of complications after AF ablation has always been a controversial issue. Akça et al. ([@ref32]) demonstrated that CF procedures are associated with lesser major complications during AF ablation than NCF ones (2.1% vs. 7.8%, p=0.01). A previous meta-analysis ([@ref42]) that included 11 studies demonstrated that the major complication rate was numerically lower in the CF group than in the NCF group; however, this did not reach statistical significance (1.3% vs. 1.9%; OR, 0.71; 95% CI, 0.29--1.73; p=0.45). With more studies included, the current meta-analysis demonstrated that the incidence of major complications was significantly lower in the CF group than in the NCF group (1.8% vs. 3.1%; OR=0.59; 95% CI, 0.37--0.95; p\<0.05).

In the current analysis, the procedure duration, ablation time, fluoroscopy duration, and radiation dose significantly reduced in the CF group compared with in the NCF group in the AF and PAF subgroups. CF-sensing catheters may reduce reliance on fluoroscopy during navigation and the time to achieve intact linear lesions, which promote safety not only for patients but also for operators.

Study limitations {#sec2-9}
-----------------

The current analysis had the following limitations: some studies were of limited quality, given their retrospective and single-center designs. Differences in operators' experience and ablation protocols may have affected the outcomes of the included studies.

Conclusion {#sec1-5}
==========

AF ablation using CF-sensing catheters has better outcomes than those NCF-sensing catheters during the 12-month follow-up period. Furthermore, the incidence of major complications using CF-sensing catheters was even lower than that using NCF-sensing catheters. The meta-analysis also demonstrated that using an optimal average CF of 18.3 g was associated with higher success and lower complication rates. Randomized controlled studies are required to assess whether catheter ablation using an optimized CF improves the long-term clinical outcome and to determine the exact optimal CF to be used in different patient subgroups.
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